Episode Summary
Executive Summary: The episode examines the controversy over anti-amyloid Alzheimer’s drugs, contrasting Aduhelm’s flawed accelerated approval with the more evidence-backed Leqembi and the delayed review of donanemab. Expert Jason Karlawish argues these drugs modestly slow decline in early-stage patients, carry real safety risks, and require major system-level support. They are promising but not a cure.
Main Topics: Anti-amyloid drugs and how they work (Priority: 5/5): The discussion explains that the latest Alzheimer’s drugs all target amyloid, but each binds different parts of the misfolded protein and reduces amyloid burden through distinct mechanisms. Aduhelm controversy and FDA credibility (Priority: 5/5): Aduhelm’s accelerated approval is presented as a regulatory failure because amyloid reduction was shown without convincing proof of patient benefit, fueling criticism of both Biogen and the FDA. Leqembi’s modest benefit and safety tradeoffs (Priority: 5/5): Leqembi is described as having evidence of slowed cognitive decline, but with risks of brain swelling and bleeding that require careful patient selection and monitoring. Donanemab delay and likely FDA concerns (Priority: 4/5): The FDA’s delayed decision on donanemab may relate to trial design, especially the requirement for both amyloid and tau evidence, and to detailed safety review. Diagnostics, monitoring, and personalized prescribing (Priority: 4/5): Karlowish explains that genetic testing, MRI, PET, and spinal fluid analysis now help determine eligibility, risk, and whether cognitive symptoms are truly due to Alzheimer’s disease. Health system capacity and dementia care gaps (Priority: 5/5): The segment stresses that current care infrastructure is under-resourced, with too few trained clinicians and long waits, making it hard to safely deliver these therapies. Future of Alzheimer’s treatment (Priority: 4/5): The interview frames anti-amyloids as a starting point rather than a cure, with the field likely to move toward better amyloid drugs or therapies targeting tau, inflammation, and other pathways.
Key Arguments: Anti-amyloid drugs all lower amyloid, but they do so differently and must be judged by whether they improve patient outcomes, not just biomarkers. Aduhelm was criticized because lowering amyloid was never convincingly linked to real clinical benefit before approval. Leqembi appears to provide a modest slowing of decline, and the speaker считает the benefit-risk balance acceptable for selected patients. Safety risks, especially brain swelling and microbleeds, are significant but can be monitored with genetics and MRI in specialized settings. The FDA delay for donanemab likely reflects unresolved questions about trial design, labeling, or safety review rather than a repeat of Aduhelm. The biggest barrier to use is not only the drugs themselves but the lack of a well-resourced dementia care system to administer and monitor them. These medicines help delay progression in early disease, but patients should not expect to notice dramatic improvement. The field may eventually shift toward presymptomatic testing and earlier intervention, similar to how heart disease and osteoporosis are managed.
Data Points: Aduhelm approval: 2021 - First anti-amyloid Alzheimer’s drug to reach FDA approval, later criticized and eventually pulled from the market by Biogen. Leqembi approval: Early 2023 - Second anti-amyloid drug to gain FDA approval after trials showed a modest slowing of cognitive decline. Donanemab review status: Delayed - FDA postponed approval pending an advisory board hearing and further review. Patient progression without drug: About 30% - After 18 months, Karlowish says around 30% of patients progress to the next disease stage. Progression reduction with drug: About 10 percentage points - He states treatment lowers progression from about 30% to about 20% over 18 months. Patients who remain stable after 18 months: About 70% - Used to illustrate the slow natural history of early Alzheimer’s disease. Biogen withdrawal of Aduhelm: Last month - The company ended sales and stopped related research. Drug targets: Amyloid and, in some trials, tau - Donanemab trials required evidence of amyloid plus tau; amyloid is the shared target across these drugs.
Pivotal Quotes: "They show promise, they're worth pursuing, but they are not a cure, they are not halting the disease." — Ariel Duhom Ross / intro framing: Sets up the episode’s central question about the value and limits of anti-amyloid drugs. "Aduhelm was a failure. Regulatory science." — Dr. Jason Karlowish: His blunt assessment of the controversial FDA approval of Aduhelm. "They show promise. They're worth pursuing, but they are not a cure. They are not halting the disease." — Dr. Jason Karlowish: His bottom-line evaluation of the anti-amyloid class near the end of the interview.
Implications: Anti-amyloid drugs are now a real but limited option for early Alzheimer’s, best used in specialized centers with testing and monitoring. The bigger challenge is building care capacity and developing better therapies that more directly halt disease.